Incyte has been granted a patent for compounds that inhibit PI3K-?, which can be used to treat various diseases including autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases. The patent also covers a method of treating diseases associated with overexpression of PI3K? kinase, such as tumors, sarcomas, lymphomas, leukemias, and various types of cancer, by administering specific compounds or their pharmaceutically acceptable salts. GlobalData’s report on Incyte gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Incyte, Peptide pharmacophores was a key innovation area identified from patents. Incyte's grant share as of September 2023 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11773102B2) discloses a method for treating diseases or disorders associated with the overexpression of PI3K? kinase. The method involves administering a therapeutically effective amount of a compound selected from a specific group of compounds or their pharmaceutically acceptable salts.
The diseases or disorders that can be treated using this method include various types of cancers such as lung cancer, melanoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, colon cancer, endometrial cancer, bladder cancer, skin cancer, cancer of the uterus, renal cancer, gastric cancer, and sarcoma. Sarcoma subtypes that can be treated include Askin's tumor, sarcoma botryoides, chondrosarcoma, Ewing's sarcoma, malignant hemangioendothelioma, malignant schwannoma, osteosarcoma, alveolar soft part sarcoma, angiosarcoma, cystosarcoma phyllodes, dermatofibrosarcoma protuberans, desmoid tumor, desmoplastic small round cell tumor, epithelioid sarcoma, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, fibrosarcoma, gastrointestinal stromal tumor, hemangiopericytoma, hemangiosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, lymphosarcoma, malignant peripheral nerve sheath tumor, neurofibrosarcoma, rhabdomyosarcoma, synovial sarcoma, and undifferentiated pleomorphic sarcoma.
Additionally, the method can be used to treat various hematological malignancies such as acute myeloid leukemia, acute monocytic leukemia, small lymphocytic lymphoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, multiple myeloma, T-cell acute lymphoblastic leukemia, cutaneous T-cell lymphoma, large granular lymphocytic leukemia, mature peripheral T-cell neoplasm, anaplastic large cell lymphoma, and lymphoblastic lymphoma.
Furthermore, the method can be applied to treat autoimmune diseases including rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, asthma, allergy, pancreatitis, psoriasis, anaphylaxis, glomerulonephritis, inflammatory bowel disease, thrombosis, meningitis, encephalitis, diabetic retinopathy, benign prostatic hypertrophy, myasthenia gravis, Sjögren's syndrome, osteoarthritis, and atherosclerosis.
The patent also mentions the possibility of combining the compound with inhibitors of JAK1, JAK2, JAK1 and JAK2, or PI3Kd for enhanced therapeutic effects.
In summary, the granted patent describes a method for treating a wide range of diseases and disorders associated with the overexpression of PI3K? kinase. The method involves administering specific compounds or their pharmaceutically acceptable salts to patients in need. This patent provides potential therapeutic options for various cancers, hematological malignancies, and autoimmune diseases.
To know more about GlobalData’s detailed insights on Incyte, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
